Medication in smoking cessation

Subject area of study: 
Smoking cessation, mental health
Title of study: 
Medication in smoking cessation
Brief outline of the study: 

This is a phase 4, randomized, double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks Varenicline Tartrate 1mg BID and Bupropion Hydrochloride 150mg BID for smoking cessation in subjects with and without a history of psychiatric disorders.

This study will examine important safety aspects (such as agitation, aggression and depression) of the drugs varenicline and bupropion compared to placebo (“dummy pills” that do not contain any medicine) and nicotine-replacement therapy (NRT or “the patch”) in smokers with or without a history of being diagnosed with a psychiatric disorder. This study will also examine how well varenicline, bupropion and NRT (“the patch”) will work to help people with and without psychiatric disorders quit smoking.

Department: 
Monash Alfred Psychiatry Research Centre (MAPrc)
Recruitment start date: 
Tue, 31/07/2012
Recruitment end date: 
Mon, 30/06/2014
Contact person title: 
Ms
Contact person first name: 
Bodil
Contact person last name: 
Hook
Contact email: 
Contact phone number: 
(03) 9076 3245
Ethics Committee Project Number: 
3/12
Do you have advertising approval?: 
Yes
Approved by: 
Alfred